Ann: Trading Policy, page-22

It would appear that FPPs could be integral to a number of different approaches to immuno-oncology including cancer vaccines and the delivery of antibodies. While the cancer vaccine development is more advanced, success with the intracellular delivery of antibodies could be a ground breaking development.

Immunotherapeutic monoclonal antibodies which include checkpoint inhibitors already list as some of the most effective treatments of cancer. The drugs act on targets outside the cell. The long-awaited development is to access intracellular targets (80% of targets reside inside cells).

The article Therapeutic Antibodies against Intracellular Tumor Antigens, published August 18, 2017 outlines current approaches to the delivery of antibodies inside the cell. The point of interest in the article relates to a discussion around the fusion of mAbs with cell-penetrating peptides. Two issues are highlighted;
1. Its difficult to predict whether sufficient drug will enter the cell to mediate a therapeutic effect particularly as CPPs are at risk of being trapped within endosomes.
2. The antibody (fragments) will undergo degradation inside the cell requiring continuous re-administration.

I have no idea about the second constraint but understand that Phylogica is all over the first with its endosome escaping FPPs and proof of concept Cre system.